What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Macular Edema (DME)
- Main trialPhase 3
- “A multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment. After screening, eligible subjects were randomized in a 1:1 ratio to the treatment group or the control group. The treatment group received BAT5906 injection, while the control group received Lucentis®. During the trial, ophthalmic examinations and safety assessments were conducted according to the protocol for efficacy and safety evaluation. Blood samples were collected for immunogenicity assessment. The…”In the company’s words, NCT07515079 on ClinicalTrials.gov
- Other names
- No Other Intervention Names
- Copy of
- Lucentis (Genentech)Tested side by side with the original in NCT05439629, NCT07515079
Other drugs for Diabetic Macular Edema (DME)
Coming up1
- 30 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Apr 2027 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | |
| Phase 3Completed | 22 Apr 2025 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration | |
| Phase 2Completed | 6 Sep 2022 | Clinical Study on the Efficacy and Safety of BAT5906 Injection | |
| Phase 1/2Completed | 6 Nov 2023 | Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema | |
| Phase 1Completed | 28 Feb 2021 | A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026